DGAP-News: EVOTEC ENTERS PARTNERSHIP WITH QUANTRO THERAPEUTICS
Hamburg, Germany, 21 July 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH ("QUANTRO"), a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases.
DGAP-News: Evotec SE / Key word(s): Miscellaneous EVOTEC ENTERS PARTNERSHIP WITH QUANTRO THERAPEUTICS 21.07.2020 / 07:30 The issuer is solely responsible for the content of this announcement.
21.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | [email protected] |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1097997 |
End of News | DGAP News Service |
|
1097997 21.07.2020